GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (OTCPK:MRMD) » Definitions » Beneish M-Score

MariMed (MariMed) Beneish M-Score : -2.83 (As of Apr. 29, 2024)


View and export this data going back to 2012. Start your Free Trial

What is MariMed Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.83 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for MariMed's Beneish M-Score or its related term are showing as below:

MRMD' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -0.93   Max: 9.95
Current: -2.83

During the past 13 years, the highest Beneish M-Score of MariMed was 9.95. The lowest was -2.83. And the median was -0.93.


MariMed Beneish M-Score Historical Data

The historical data trend for MariMed's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Beneish M-Score Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -1.57 -2.56 -0.61 -2.83

MariMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.61 -0.83 -1.86 -2.52 -2.83

Competitive Comparison of MariMed's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where MariMed's Beneish M-Score falls into.



MariMed Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of MariMed for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9568+0.528 * 1.0759+0.404 * 1.0738+0.892 * 1.1089+0.115 * 0.7422
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1766+4.679 * -0.056403-0.327 * 1.4566
=-2.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $8.0 Mil.
Revenue was 38.899 + 38.8 + 36.519 + 34.38 = $148.6 Mil.
Gross Profit was 17.317 + 16.838 + 16.376 + 15.388 = $65.9 Mil.
Total Current Assets was $51.4 Mil.
Total Assets was $196.1 Mil.
Property, Plant and Equipment(Net PPE) was $102.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $8.6 Mil.
Selling, General, & Admin. Expense(SGA) was $50.7 Mil.
Total Current Liabilities was $30.9 Mil.
Long-Term Debt & Capital Lease Obligation was $76.2 Mil.
Net Income was -10.169 + -4.259 + -0.958 + -0.645 = $-16.0 Mil.
Non Operating Income was -10.803 + -0.556 + -0.474 + -1.046 = $-12.9 Mil.
Cash Flow from Operations was 3.234 + 7.9 + 1.275 + -4.499 = $7.9 Mil.
Total Receivables was $7.5 Mil.
Revenue was 35.83 + 33.912 + 32.986 + 31.282 = $134.0 Mil.
Gross Profit was 15.812 + 16.164 + 15.005 + 16.976 = $64.0 Mil.
Total Current Assets was $44.1 Mil.
Total Assets was $152.2 Mil.
Property, Plant and Equipment(Net PPE) was $77.3 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.7 Mil.
Selling, General, & Admin. Expense(SGA) was $38.9 Mil.
Total Current Liabilities was $26.5 Mil.
Long-Term Debt & Capital Lease Obligation was $30.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7.986 / 148.598) / (7.527 / 134.01)
=0.053742 / 0.056167
=0.9568

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(63.957 / 134.01) / (65.919 / 148.598)
=0.477255 / 0.443606
=1.0759

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (51.432 + 102.114) / 196.123) / (1 - (44.146 + 77.285) / 152.202)
=0.217093 / 0.202172
=1.0738

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=148.598 / 134.01
=1.1089

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.714 / (4.714 + 77.285)) / (8.574 / (8.574 + 102.114))
=0.057489 / 0.077461
=0.7422

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(50.721 / 148.598) / (38.875 / 134.01)
=0.34133 / 0.29009
=1.1766

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((76.247 + 30.862) / 196.123) / ((30.577 + 26.49) / 152.202)
=0.546132 / 0.374943
=1.4566

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-16.031 - -12.879 - 7.91) / 196.123
=-0.056403

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

MariMed has a M-score of -2.83 suggests that the company is unlikely to be a manipulator.


MariMed Beneish M-Score Related Terms

Thank you for viewing the detailed overview of MariMed's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (MariMed) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R Levine 10 percent owner C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Timothy Shaw officer: Chief Operating Officer C/O MARIMED INC, 10 OCEANA WAY, NORWOOD MA 02062
Kathleen Tucker director C/O 10 OCEANA WAY, 2ND FLOOR, NORWOOD MA 02062
Susan M. Villare officer: Chief Financial Officer C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
Selhub Eva M.d. director C/O MARIMED INC., 10 OCEANA WAY, NORWOOD MA 02062
David R Allen director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Thomas Kidrin director 11 ROYAL ROAD, BROOKLINE MA 02445
Edward J Gildea director C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
Jay Coleman director 310 EAST 46TH ST. APT 9 F, NEW YORK NY 10017
Robert N Fireman director 145 ROSEMARY ST. SUITE H-2, NEEDHAM MA 02494
Worlds.com, Inc. director, 10 percent owner, officer: PRESIDENT, CEO, other: TREASURER, SECRETARY 11 ROYAL ROAD, BROOKLINE MA 02445
Christopher John Ryan officer: CFO, VICE PRESIDENT 11 ROYAL RD, BROOKLINE MA 02445